Phase III study of gefitinib versus erlotinib in patients with previously treated lung adenocarcinoma.

Trial Profile

Phase III study of gefitinib versus erlotinib in patients with previously treated lung adenocarcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2016

At a glance

  • Drugs Erlotinib (Primary) ; Gefitinib (Primary)
  • Indications Adenocarcinoma; Lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Mar 2016 Results published in the Journal of Clinical Oncology.
    • 17 Oct 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 31 May 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top